News
Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention
Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week.
ACIP votes to expand recommendation for Pfizer’s RSV vaccine Abrysvo to include adults aged 50 to 59 at increased risk of disease
the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine,
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...
The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...
A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback